Literature DB >> 32796029

An alternative model for type I interferon induction downstream of human TLR2.

Timo Oosenbrug1, Michel J van de Graaff2, Mariëlle C Haks3, Sander van Kasteren2, Maaike E Ressing4.   

Abstract

Surface-exposed Toll-like receptors (TLRs) such as TLR2 and TLR4 survey the extracellular environment for pathogens. TLR activation initiates the production of various cytokines and chemokines, including type I interferons (IFN-I). Downstream of TLR4, IFNβ secretion is only vigorously triggered in macrophages when the receptor undergoes endocytosis and switches signaling adaptor; surface TLR4 engagement predominantly induces proinflammatory cytokines via the signaling adaptor MyD88. It is unclear whether this dichotomy is generally applicable to other TLRs, cell types, or differentiation states. Here, we report that diverse TLR2 ligands induce an IFN-I response in human monocyte-like cells, but not in differentiated macrophages. This TLR2-dependent IFN-I signaling originates from the cell surface and depends on MyD88; it involves combined activation of the transcription factors IRF3 and NF-κB, driven by the kinases TBK1 and TAK1-IKKβ, respectively. TLR2-stimulated monocytes produced modest IFNβ levels that caused productive downstream signaling, reflected by STAT1 phosphorylation and expression of numerous interferon-stimulated genes. Our findings reveal that the outcome of TLR2 signaling includes an IFN-I response in human monocytes, which is lost upon macrophage differentiation, and differs mechanistically from IFN-I-induction through TLR4. These findings point to molecular mechanisms tailored to the differentiation state of a cell and the nature of receptors activated to control and limit TLR-triggered IFN-I responses.
© 2020 Oosenbrug et al.

Entities:  

Keywords:  Toll-like receptor (TLR); cell differentiation; cell surface; human; innate immunity; interferon; monocyte

Year:  2020        PMID: 32796029      PMCID: PMC7573265          DOI: 10.1074/jbc.RA120.015283

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  87 in total

Review 1.  Toll-like receptor control of the adaptive immune responses.

Authors:  Akiko Iwasaki; Ruslan Medzhitov
Journal:  Nat Immunol       Date:  2004-10       Impact factor: 25.606

2.  Adaptor Protein-3-Mediated Trafficking of TLR2 Ligands Controls Specificity of Inflammatory Responses but Not Adaptor Complex Assembly.

Authors:  Tanja Petnicki-Ocwieja; Aurelie Kern; Tess L Killpack; Stephen C Bunnell; Linden T Hu
Journal:  J Immunol       Date:  2015-09-30       Impact factor: 5.422

Review 3.  IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors.

Authors:  Kenya Honda; Tadatsugu Taniguchi
Journal:  Nat Rev Immunol       Date:  2006-09       Impact factor: 53.106

4.  Heterodimerization of TLR2 with TLR1 or TLR6 expands the ligand spectrum but does not lead to differential signaling.

Authors:  Katja Farhat; Sabine Riekenberg; Holger Heine; Jennifer Debarry; Roland Lang; Jörg Mages; Ute Buwitt-Beckmann; Kristina Röschmann; Günther Jung; Karl-Heinz Wiesmüller; Artur J Ulmer
Journal:  J Leukoc Biol       Date:  2007-12-03       Impact factor: 4.962

5.  A role for the adaptor proteins TRAM and TRIF in toll-like receptor 2 signaling.

Authors:  Nadra J Nilsen; Gregory I Vladimer; Jørgen Stenvik; M Pontus A Orning; Maria V Zeid-Kilani; Marit Bugge; Bjarte Bergstroem; Joseph Conlon; Harald Husebye; Amy G Hise; Katherine A Fitzgerald; Terje Espevik; Egil Lien
Journal:  J Biol Chem       Date:  2014-12-11       Impact factor: 5.157

6.  Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling.

Authors:  Karen Bieback; Egil Lien; Ingo M Klagge; Elita Avota; Jürgen Schneider-Schaulies; W Paul Duprex; Herrmann Wagner; Carsten J Kirschning; Volker Ter Meulen; Sibylle Schneider-Schaulies
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

7.  Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway.

Authors:  Masahiro Yamamoto; Shintaro Sato; Hiroaki Hemmi; Katsuaki Hoshino; Tsuneyasu Kaisho; Hideki Sanjo; Osamu Takeuchi; Masanaka Sugiyama; Masaru Okabe; Kiyoshi Takeda; Shizuo Akira
Journal:  Science       Date:  2003-07-10       Impact factor: 47.728

Review 8.  The Roles of Type I Interferon in Bacterial Infection.

Authors:  Gayle M Boxx; Genhong Cheng
Journal:  Cell Host Microbe       Date:  2016-06-08       Impact factor: 21.023

9.  Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells.

Authors:  T Yoshimori; A Yamamoto; Y Moriyama; M Futai; Y Tashiro
Journal:  J Biol Chem       Date:  1991-09-15       Impact factor: 5.157

Review 10.  Interferon-stimulated genes and their antiviral effector functions.

Authors:  John W Schoggins; Charles M Rice
Journal:  Curr Opin Virol       Date:  2011-12       Impact factor: 7.090

View more
  4 in total

1.  Multivariate Analysis Reveals That Unsubstituted β-Ring and C8-Keto Structures Are Important Factors for Anti-Inflammatory Activity of Carotenoids.

Authors:  Yuki Manabe; Nami Tomonaga; Takashi Maoka; Tatsuya Sugawara
Journal:  Nutrients       Date:  2021-10-21       Impact factor: 5.717

2.  Anti-Inflammatory Effect of an O-2-Substituted (1-3)-β-D-Glucan Produced by Pediococcus parvulus 2.6 in a Caco-2 PMA-THP-1 Co-Culture Model.

Authors:  Sara Notararigo; Encarnación Varela; Anna Otal; María Antolín; Francisco Guarner; Paloma López
Journal:  Int J Mol Sci       Date:  2022-01-28       Impact factor: 5.923

3.  TIRAP/Mal Positively Regulates TLR8-Mediated Signaling via IRF5 in Human Cells.

Authors:  Kaja Elisabeth Nilsen; Astrid Skjesol; June Frengen Kojen; Terje Espevik; Jørgen Stenvik; Maria Yurchenko
Journal:  Biomedicines       Date:  2022-06-22

4.  An Attenuated Strain of Human Cytomegalovirus for the Establishment of a Subviral Particle Vaccine.

Authors:  Steffi Krauter; Nicole Büscher; Eric Bräuchle; Samira Ortega Iannazzo; Inessa Penner; Nadine Krämer; Patricia Gogesch; Simone Thomas; Marina Kreutz; Mario Dejung; Anja Freiwald; Falk Butter; Zoe Waibler; Bodo Plachter
Journal:  Vaccines (Basel)       Date:  2022-08-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.